Table 4. Effect of prepartum control or conjugated linoleic acids (CLA) supplementation on proportion of health disorders for dairy cows from calving until 30 days postpartum.
| Treatmentsa | ||||
|---|---|---|---|---|
| Health disorders, % (nc/nt)b | Control | CLA | SEM | P-value |
| Hyperketonemia | ||||
| Day 1 postpartum | 2.9 (1/34) | 0 (0/30) | 3.07 | 0.98 |
| Day 7 postpartum | 8.8 (3/34) | 0 (0/30) | 4.86 | 0.97 |
| Day 14 postpartum | 23.5 (8/34) | 3.3 (1/30) | 5.33 | 0.05 |
| Day 30 postpartum | 5.9 (2/34) | 0 (0/30) | 4.03 | 0.98 |
| Milk fever | 1.2 (2/141) | 0.6 (1/143) | 0.80 | 0.59 |
| Retained placenta | 4.9 (7/141) | 2.1 (3/143) | 1.52 | 0.20 |
| Displaced abomasum | 0.7 (1/141) | 0.6 (1/143) | 0.70 | 0.99 |
| Mastitisc | 31.8 (45/141) | 31.7 (46/143) | 4.66 | 0.98 |
| Lameness | 5.6 (8/141) | 4.8 (7/143) | 1.94 | 0.75 |
| Death | 1.4 (2/141) | 0.7 (1/143) | 0.84 | 0.56 |
a Treatments: Control (n = 141) cows supplemented with 78 g of Energy Booster 100 (Milk Specialties Global, Eden Prairie, MN) and CLA (n = 143) cows supplemented with 100 g/day of Lutrell Pure (BASF, Ludwigshafen, Germany). Supplementation was by individual topdress of product mixed with 200 g corn gluten feed for 16 days prepartum.
b Number of new cases (nc) divided by total number of cows (nt).
c Milk samples from cows with somatic cells count greater than 200 cells x 103/mL [18] or diagnosed with clinical mastitis.